Yogavahi Action Of Rasasindoor In Essential Hypertension: A Comprehensive Ayurvedic And Pharmacological Review

Abstract

Background: Rasasindoor, a classical Ayurvedic Rasaushadhi prepared through Puta-processed Parada (mercury) and Gandhaka (sulphur), is acclaimed for its Yogavahi property—facilitating targeted drug delivery without losing its own identity. Essential hypertension, a chronic lifestyle disorder characterized by persistently elevated blood pressure, poses significant cardiovascular risks. Modern pharmacotherapy often addresses symptoms, but side effects and drug resistance are frequent. This review explores the potential of Rasasindoor as a Yogavahi agent in the management of essential hypertension by integrating classical Ayurvedic principles and contemporary pharmacological insights. Aim: To analyze the Yogavahi action of Rasasindoor in the context of essential hypertension based on classical Ayurvedic texts and modern pharmacological interpretations. Objectives: To review classical Ayurvedic references describing the Yogavahi quality of Rasasindoor. To assess the relevance of Rasasindoor in systemic drug delivery, particularly in cardiovascular disorders like essential hypertension. To correlate the pharmacological actions of Rasasindoor with mechanisms of antihypertensive therapy. Methodology: This is a conceptual and literary review based on Ayurvedic texts like Rasa Ratna Samuccaya, Rasa Tarangini, and Bhaishajya Ratnavali, as well as pharmacological databases and scientific literature. The review focused on the therapeutic dynamics of Rasasindoor including its Yogavahi property, potential antioxidant, vasodilatory, and neurohormonal modulating effects relevant to essential hypertension. No clinical or experimental data were included. Results: Rasasindoor, due to its Sookshma, Teekshna, and Yogavahi properties, demonstrates potential for precise cellular targeting in systemic disorders like hypertension. Classical properties such as Rasayana, Balya, and Hridaya strengtheners align with modern pharmacological actions like vasorelaxation, nitric oxide modulation, and antioxidant effects. Preliminary modern studies on mercury-based nanomedicine suggest enhanced bioavailability and tissue-specific drug delivery. Conclusion: Rasasindoor, as a Yogavahi agent, offers a promising integrative approach in the management of essential hypertension by enhancing the efficacy of co-administered drugs, targeting cardiovascular tissues, and minimizing systemic toxicity. Future pharmacodynamic and clinical validation is warranted to establish its safety and efficacy profiles.